PF-Atlas › Clinical Trials › NCT00699062
Effect of Montelukast on the Airway Remodeling
singular · Phase 4
Registry ID
NCT00699062
Phase
Phase 4
Status
Completed
Drug / intervention
singular
Sponsor
Chinese Academy of Medical Sciences
Start
2010-01
Enrollment
40
Locations
1
About this trial
The distal lung contributes to asthmatic airway remodeling which is observed from early onset of the disease. Cysteinyl leukotrienes (CysLT) play important role in the pathogenesis of airway remodeling and antileukotrienes work to exert a certain degree of anti-inflammatory effect. The cysteinyl leukotriene antagonist Montelukast has been in vivo shown to significantly inhibit ovalbumin induced airway smooth muscle hyperplasia and subepithelial fibrosis in sensitized mice. This study aims to evaluate if Montelukast could reverse airway remodeling in asthma patients by a non-invasive approach-HRCT.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT00699062 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.